The importance of measuring drug target residence times

Posted: 21 September 2015 | BioTek

The Synergy Neo2 Multi-Mode Reader is designed to provide high temporal resolution in drug target kinetics applications…

BioTek’s Synergy Neo2 Multi-Mode Microplate Reader

Target-based approaches to drug discovery have traditionally sought compounds of high binding affinity to the drug target. Affinity of inhibitory compounds is classically assessed using a labeled ligand which is competed from binding to the drug target. The important attributes of the inhibitory compound are its IC50 evaluated from inhibitor dose-response curves and its dissociation constant of binding, Ki as calculated from this empirical data using the Cheng-Prusoff equation, knowing the concentration of labeled ligand used in the assay and its equilibrium dissociation constant, Kd.

However, in recent years drug target kinetics has become an alternate method of evaluating inhibitors rather than the thermodynamic approach as outlined above. In these assays, the reciprocal of the inhibitor off rate, 1/koff, or the inhibitor residence time on the drug target, computed with the Motulsky and Mahan equation, becomes the important attribute. Various studies have shown that drug residence times are a promising early stage indicator of in vivo drug activity.

Accurately measuring inhibitor residence times requires detection of readouts with adequate temporal resolution to determine the key variables of the Motulsky and Mahan equation. This is particularly important for ratiometric readouts where the readout consists of a ratio of two signals. The Synergy Neo2 Multi-Mode Reader is designed to provide high temporal resolution in drug target kinetics applications, even with ratiometric measurements like HTRF®, by the simultaneous detection of time-resolved fluorescence at 620 and 665nm which provides improved temporal resolution and more accurate data than fast sequential measurements. With a high power Xe flashlamp for excitation that limits the number of flashes/measurement required for good sensitivity, along with its simultaneous detection capabilities, the Synergy Neo2 can provide temporal resolution < 1sec with high sensitivity for drug target kinetic studies…

The rest of this article is restricted - login or subscribe free to access

Screening the future innovations in drug discoveryThank you for visiting our website. To access this content in full you'll need to login. It's completely free to subscribe, and in less than a minute you can continue reading. If you've already subscribed, great - just login.

Why subscribe? Join our growing community of thousands of industry professionals and gain access to:

  • quarterly issues in print and/or digital format
  • case studies, whitepapers, webinars and industry-leading content
  • breaking news and features
  • our extensive online archive of thousands of articles and years of past issues
  • ...And it's all free!

Click here to Subscribe today Login here


Related organisations